Results 51 to 60 of about 23,086 (212)
First‐line diagnostic tests to intercept primary heart involvement in systemic sclerosis: Clinical associations from the SPRING‐SIR registry
European Journal of Clinical Investigation, Volume 55, Issue 12, December 2025.Primary heart involvement (pHI) is a severe but often overlooked complication of systemic sclerosis (SSc), linked to heart failure, arrhythmias and mortality. In a study of 600 patients from the Italian SPRING‐SIR registry, 25% had ECG or echocardiographic signs of pHI at baseline, associated with older age, diffuse skin disease and intestinal symptoms.Antonio Tonutti, Francesca Motta, Rossella De Angelis, Edoardo Cipolletta, Clodoveo Ferri, Gianluigi Bajocchi, Silvia Bellando‐Randone, Cosimo Bruni, Martina Orlandi, Giovanni Zanframundo, Rosario Foti, Giovanna Cuomo, Alarico Ariani, Edoardo Rosato, Gemma Lepri, Francesco Girelli, Elisabetta Zanatta, Silvia Laura Bosello, Ilaria Cavazzana, Francesca Ingegnoli, Fabio Cacciapaglia, Giuseppe Murdaca, Giuseppina Abignano, Giorgio Pettiti, Alessandra Della Rossa, Maurizio Caminiti, Anna Maria Iuliano, Giovanni Ciano, Lorenzo Beretta, Gianluca Bagnato, Ennio Lubrano, Ilenia De Andres, Luca Idolazzi, Marta Saracco, Cecilia Agnes, Corrado Campochiaro, Marco Fornaro, Federica Lumetti, Amelia Spinella, Luca Magnani, Giacomo De Luca, Veronica Codullo, Elisa Visalli, Carlo Iandoli, Antonietta Gigante, Greta Pellegrino, Erika Pigatto, Maria Grazia Lazzaroni, Enrico De Lorenzis, Gianna Mennillo, Marco Di Battista, Giuseppa Pagano‐Mariano, Federica Furini, Licia Vultaggio, Simone Parisi, Clara Lisa Peroni, Gerolamo Bianchi, Enrico Fusaro, Gian Domenico Sebastiani, Marcello Govoni, Salvatore D'Angelo, Franco Cozzi, Franco Franceschini, Serena Guiducci, Lorenzo Dagna, Andrea Doria, Dilia Giuggioli, Valeria Riccieri, Carlo Salvarani, Florenzo Iannone, Marco Matucci‐Cerinic, Carlo Selmi, Maria De Santis, on behalf of SPRING‐SIR (Systemic Sclerosis PRogression INvestiGation group of the Italian Society for Rheumatology), Giorgio Amato, Alessia Benenati, Francesca Calabrese, Renato Carignola, Francesca Dall’Ara, Angelo De Cata, Claudio Di Vico, Marica Doveri, Nicoletta Romeo, Elena Generali, Gianluca Sambataro, Rossella Talotta, Alberto Lo Gullo, Carlo Scirè, Greta Carrara, Giampiero Landolfi, Davide Rozza, Anna Zanetti +91 morewiley +1 more sourcePain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study
Arthritis Research & TherapyChronic pain and inflammation are common features of rheumatic conditions such as Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), often needing prolonged medication treatment for effective management.D. Currado, F. Saracino, P. Ruscitti, A. Marino, I. Pantano, Marta Vomero, O. Berardicurti, V. Pavlych, C. Di Vico, Francesco Caso, Luisa Costa, M. Tasso, F. Camarda, F. Misceo, Francesco De Vincenzo, A. Corrado, L. Arcarese, Amelia Rigon, M. Vadacca, E. Corberi, Lyubomyra Kun, F. Trunfio, A. Pilato, Ludovica Lamberti, F. Cantatore, F. Perosa, G. Guggino, R. Scarpa, Paola Cipriani, F. Ciccia, Roberto Giacomelli, L. Navarini +31 moresemanticscholar +1 more sourceEnfermería y artritis reumatoide. Revisión bibliográfica [PDF]
, 2016 La artritis reumatoide es una enfermedad inflamatoria crónica, autoinmune sistémica y multiorgánica, de origen desconocido. Afecta de esta manera, a multitud de tejidos y órganos, comprometiendo principalmente a las articulaciones con sinovitis ...Pasquier Álvarez, Miriamcore Impact of Concomitant Methotrexate Use and Prior Biologic Disease‐Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial
ACR Open Rheumatology, Volume 7, Issue 10, October 2025.Objective
We evaluate tofacitinib efficacy and safety in patients with juvenile idiopathic arthritis (JIA) stratified by concomitant methotrexate and prior biologic disease‐modifying antirheumatic drug (bDMARD) treatment. Methods
In this two part, double‐blind, randomized withdrawal Phase 3 trial (NCT02592434), patients (2–<18 years) with JIA received ...Nicolino Ruperto, Daniel J. Lovell, Olga Synoverska, Carlos Abud‐Mendoza, Alberto Spindler, Yulia Vyzhga, Iris Reyhan, Lyudmila Grebenkina, Irit Tirosh, Lisa Imundo, Peter Chiraseveenuprapund, Daniel J Kingsbury, Betul Sozeri, Sheetal S. Vora, Sampath Prahalad, Elena Zholobova, Kevin D. Roberts, Gosford Sawyerr, Andreas Blum, Andrea Shapiro, Annette Diehl, Abbas Ebrahim, Pascal Klaus, Alberto Martini, Hermine I. Brunner, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) +25 morewiley +1 more sourceEditorial I
Revista Argentina de Reumatología, 2020
En la primera edición del año 2020, se presentan datos del Registro Argentino de Miopatías Inflamatorias de la Sociedad Argentina de Reumatología. En esta ocasión, el registro nos aporta hallazgos significativos en cuanto a los métodos diagnósticos en ...Darío Scublinskydoaj +1 more sourceLa reumatología del siglo 21
Revista Reumatología al Día, 2022 El término REUMATISMO fue introducido por Galeno en el siglo II DC. Proviene de la palabra “rheos” que significa “fluir” puesto que, en aquellos tiempos, se creía que el reumatismo aparecía por un flujo de un “humor” desde el cerebro hacia las ...Carlos Rios Acostadoaj Sobre los efectos adversos en la vida real
Revista Argentina de Reumatología, 2016
En los tiempos en que la terapéutica farmacológica estaba en sus inicios, allá por fines del siglo XIX, se publica en The Lancet uno de los primeros reportes científicos de efectos adversos, que se trataba de las drogas anestésicas utilizadas en dicho ...Darío Scublinskydoaj +1 more sourceChanges in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
Scientific Reports, 2021 The better understanding of the safety of biologic DMARDs (bDMARDs), as well as the emergence of new bDMARDs against different therapeutic targets and biosimilars have likely influenced the use patterns of these compounds over time. The aim of this study Carlos Sánchez-Piedra, Diana Sueiro-Delgado, Javier García-González, Inmaculada Ros-Vilamajo, Agueda Prior-Español, Manuel José Moreno-Ramos, Blanca Garcia-Magallon, Jerusalen Calvo-Gutiérrez, Yanira Perez-Vera, Raquel Martín-Domenech, Dolores Ruiz-Montesino, Paloma Vela-Casasempere, Lorena Expósito, Fernando Sánchez-Alonso, Enrique González-Davila, Federico Díaz-González +15 moredoaj +1 more source